Disability and therapeutic response in paediatric neuromyelitis optica spectrum disorder: A case series from Iran

Seyed Mohammad Baghbanian, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Nasrin Asgari

Abstract


8

                                                                                         

ABSTRACT

Objectives:

The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.

Materials & Methods

Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).

Results

All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.

Conclusion:

Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 % of cases to AZA, RTX seemed to decrease the relapse rate.


Keywords


Neuromyelitis optica spectrum disorder, Paediatric, Disability, Treatment

Full Text:

PDF

12

References


Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMOSD Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14; 85(2):177-89.

Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106–2112.

Wegner C. Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. Clin Neurol Neurosurg 2013; 115: S38–S41.

McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008 Jul 8;71(2):93-100

Chitnis T, Ness J, Krupp L, Waubant E Et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016 Jan 19;86(3):245-52.

Huppke P, Blüthner M, Bauer O, et al, Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology. 2010 Nov 9;75(19):1740-4.

Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75:1084–1088.

Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010; 291: 52-6

Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15; 388:222-231.

Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol. 2016 Nov 1;73(11):1342-1348.

Nosadini M, Alper G, Riney CJ et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1): e188.




DOI: https://doi.org/10.22037/ijcn.v13i3.22715

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Iranian Journal of Child Neurology